Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: Swift Biosciences, Bio-Rad, and Exiqon


Swift Biosciences recently launched myT KRAS, the third product in its myT Primer menu of reagents to detect cancer mutations.

The myT KRAS kit provides 1 percent sensitivity for seven key mutations in codons 12 and 13 with little or no breakthrough from wild type, resulting in an assay with a definitive yes/no answer over a wide dynamic range, Swift said.

The assay works well with both frozen and formalin-fixed, paraffin-embedded samples, and each package includes sufficient reagents to test 30 samples, the company said.

Other myT Primers include myT BRAF and myT BRAF-Ultra.

Bio-Rad this week introduced its ddPCR library quantification kit for Illumina TruSeq sample preparation protocols.

Used with Bio-Rad's QX100 Droplet Digital PCR system, the new kit offers researchers a way to precisely and directly measure amplifiable library concentrations, Bio-Rad said.

The TruSeq sample prep method is used on Illumina's MiSeq and HiSeq sequencing platforms. Using the ddPCR library quantification kit to quantify TruSeq DNA libraries, maximizes the number of useable reads, enables consistent loading, and optimizes the utilization of every sequencing run, Bio-Rad said. The resulting data provide additional measures of library quality not provided by other methods, including the percentage of nonamplifiable species such as adaptor dimers as well as the size range of library inserts, the company said.

Exiqon has launched the third generation of its microRNA qPCR Focus Panel for preclinical toxicology research.

The new version of the panel will allow researchers engaged in toxicology and organ injury studies to analyze a panel of carefully selected microRNAs in biofluids such as urine and serum or plasma. A complete panel of 87 wet-lab validated microRNA assays is available for four species; human, rat, monkey, and dog. The panels also contain eight control assays specifically developed by Exiqon to ensure that rigorous quality control of the biofluid samples is an integrated part of the process.